1749-6632/asset/olbannerleft.gif?v=1&s=8fb953593f8a3a4cb38ee9a3145fd71827e572df)
1749-6632/asset/olbannerright.gif?v=1&s=5a341577ed7e4911512db03f5c6858a34802fd52)
Rationale and Overview of the Raloxifene Use for the Heart (RUTH) Trial
Article first published online: 25 JAN 2006
DOI: 10.1111/j.1749-6632.2001.tb04018.x
Issue
1749-6632/asset/cover.gif?v=1&s=ab6276ce206ff2a11aab60a58914347cab6db545 "Annals of the New York Academy of Sciences")
Annals of the New York Academy of Sciences
Volume 949, SELECTIVE ESTROGEN RECEPTOR MODULATORS (SERMs) pages 181–185, December 2001
Additional Information
How to Cite
MOSCA, L. (2001), Rationale and Overview of the Raloxifene Use for the Heart (RUTH) Trial. Annals of the New York Academy of Sciences, 949: 181–185. doi: 10.1111/j.1749-6632.2001.tb04018.x
Publication History
- Issue published online: 25 JAN 2006
- Article first published online: 25 JAN 2006
- Abstract
- Article
- References
- Cited By
Keywords:
- selective estrogen receptor modulator;
- hormone replacement therapy;
- raloxifene;
- clinical trials;
- women;
- risk factors;
- menopause;
- breast cancer;
- osteoporosis
Abstract: Raloxifene is a selective estrogen receptor modulator (SERM) that has beneficial effects on several cardiovascular risk factors and has also been associated with a reduced risk of breast cancer in osteoporosis prevention trials. The Raloxifene Use for the Heart (RUTH) study was designed to test the hypothesis that, compared to placebo, raloxifene at 60 mg/day (1) lowers the risk of the combined end point of coronary death, nonfatal myocardial infarction (MI), and hospitalized acute coronary syndromes other than MI and (2) reduces the risk of invasive breast cancer (coprimary end point) in women at high risk for major coronary events based on established cardiovascular disease (CVD) or multiple risk factors. RUTH is a double-blind, placebo-controlled, randomized, clinical trial of 10,101 women aged 55 years or older from 26 countries and is expected to be completed in approximately 5 years.